126 related articles for article (PubMed ID: 37917926)
1. Exergaming Improves Cardiac Risk Factors in Prostate Cancer Patients: A Single-Blinded Randomized Controlled Trial.
Villumsen BR; Frystyk J; Jørgensen MG; Hørdam B; Borre M
Games Health J; 2024 Apr; 13(2):93-99. PubMed ID: 37917926
[No Abstract] [Full Text] [Related]
2. A lifestyle intervention of weight loss via a low-carbohydrate diet plus walking to reduce metabolic disturbances caused by androgen deprivation therapy among prostate cancer patients: carbohydrate and prostate study 1 (CAPS1) randomized controlled trial.
Freedland SJ; Howard L; Allen J; Smith J; Stout J; Aronson W; Inman BA; Armstrong AJ; George D; Westman E; Lin PH
Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):428-437. PubMed ID: 30664736
[TBL] [Abstract][Full Text] [Related]
3. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
Usmani N; Ghosh S; Sanghera KP; Ong AD; Koul R; Dubey A; Ahmed S; Quon H; Yee D; Parliament M; Sivananthan G; Hunter W; Danielson B; Rowe L; McDonald M; Kim JO
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):317-326. PubMed ID: 35907513
[TBL] [Abstract][Full Text] [Related]
4. Home-based 'exergaming' was safe and significantly improved 6-min walking distance in patients with prostate cancer: a single-blinded randomised controlled trial.
Villumsen BR; Jorgensen MG; Frystyk J; Hørdam B; Borre M
BJU Int; 2019 Oct; 124(4):600-608. PubMed ID: 31012238
[TBL] [Abstract][Full Text] [Related]
5. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
[TBL] [Abstract][Full Text] [Related]
6. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
[TBL] [Abstract][Full Text] [Related]
7. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer.
Algotar AM; Hsu CH; Chow HH; Dougherty ST; Babiker HM; Marrero DG; Abraham I; Kumar R; Ligibel JA; Courneya KS; Smith TE; Jones PA; Lopez JN; Niemiro G; Ramakumar S; Hoy RD; Mack C; Thomson CA
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):903-909. PubMed ID: 33767355
[TBL] [Abstract][Full Text] [Related]
9. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.
Ziaran S; Goncalves FM; Breza J
World J Urol; 2013 Apr; 31(2):289-92. PubMed ID: 22898989
[TBL] [Abstract][Full Text] [Related]
10. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
Østergren PB; Kistorp C; Fode M; Bennedbaek FN; Faber J; Sønksen J
BJU Int; 2019 Apr; 123(4):602-611. PubMed ID: 30388320
[TBL] [Abstract][Full Text] [Related]
11. Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients.
Hvid T; Lindegaard B; Winding K; Iversen P; Brasso K; Solomon TP; Pedersen BK; Hojman P
Cancer Causes Control; 2016 Feb; 27(2):165-74. PubMed ID: 26573844
[TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy improves the in vitro capacity of high-density lipoprotein (HDL) to receive cholesterol and other lipids in patients with prostate carcinoma.
Albuquerque CP; Freitas FR; Martinelli AEM; Lima JH; Coelho RF; Serrano CV; Nahas WC; Kalil Filho R; Maranhão RC
Lipids Health Dis; 2020 Jun; 19(1):133. PubMed ID: 32522195
[TBL] [Abstract][Full Text] [Related]
14. Metabolic effects of androgen deprivation therapy.
Choi SM; Kam SC
Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.
Shahani S; Braga-Basaria M; Basaria S
J Clin Endocrinol Metab; 2008 Jun; 93(6):2042-9. PubMed ID: 18349064
[TBL] [Abstract][Full Text] [Related]
16. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer.
Mahalingam D; Hanni S; Serritella AV; Fountzilas C; Michalek J; Hernandez B; Sarantopoulos J; Datta P; Romero O; Pillai SMA; Kuhn J; Pollak M; Thompson IM
Oncotarget; 2023 Jun; 14():622-636. PubMed ID: 37335291
[TBL] [Abstract][Full Text] [Related]
17. Response of the insulin-like growth factor (IGF) system to IGF-IR inhibition and androgen deprivation in a neoadjuvant prostate cancer trial: effects of obesity and androgen deprivation.
Dean JP; Sprenger CC; Wan J; Haugk K; Ellis WJ; Lin DW; Corman JM; Dalkin BL; Mostaghel E; Nelson PS; Cohen P; Montgomery B; Plymate SR
J Clin Endocrinol Metab; 2013 May; 98(5):E820-8. PubMed ID: 23533230
[TBL] [Abstract][Full Text] [Related]
18. [Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone].
Terrier JE; Mottet N
Prog Urol; 2013 Feb; 23(2):88-95. PubMed ID: 23352300
[TBL] [Abstract][Full Text] [Related]
19. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
[TBL] [Abstract][Full Text] [Related]
20. Effects of six months of aerobic and resistance training on metabolic markers and bone mineral density in older men on androgen deprivation therapy for prostate cancer.
Papadopoulos E; Mina DS; Culos-Reed N; Durbano S; Ritvo P; Sabiston CM; Krahn M; Tomlinson G; O'Neill M; Iqbal A; Timilshina N; Matthew A; Warde P; Alibhai SMH
J Geriatr Oncol; 2020 Sep; 11(7):1074-1077. PubMed ID: 32143995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
